Samsung Bioepis is a biopharmaceutical company focused on developing and commercializing biosimilars, which are biologic drugs that closely resemble existing biologic medications. Established in 2012 as a joint venture between Samsung Biologics and Biogen, the company became a wholly owned subsidiary of Samsung Biologics in 2022. Its mission is to enhance patient access to high-quality medicines through innovative science and technology. The company specializes in biosimilar development, ensuring that its products meet high standards of quality, safety, and efficacy. Samsung Bioepis collaborates with partners like Biogen and Organon to market its biosimilars globally. Notable products include Opuviz, recently approved by the European Commission, along with other biosimilars targeting conditions such as rheumatoid arthritis and cancer. Through its strategic partnerships and commitment to innovation, Samsung Bioepis aims to expand access to affordable biologic therapies worldwide.